Tempus Platform
AI-enabled precision medicine platform for oncology and other diseases
Platform · Cloud SaaSCompany source
Company profile
About Tempus
Tempus uses data and AI to create precision medicine services, including diagnostics for oncology, cardiology, radiology, and more.
Company description Tempus official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Tempus?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- oncology
Who it serves
- providers
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Pretreatment Tumor NECTIN4 RNA Expression Is Associated with First-line Enfortumab Vedotin Plus Pembrolizumab Efficacy in Metastatic Urothelial Cancer.European urology · Sep 24, 2026
Genomic and Transcriptomic Correlates of Deep PSA Response in Patients with Metastatic Androgen Pathway Modulation-Sensitive Prostate Cancer.The oncologist · Sep 17, 2026
Integrative pipeline to profile and target endocrine therapy-insensitive cell populations in ER+ breast cancer.bioRxiv : the preprint server for biology · Sep 16, 2026
scDiagnostics: systematic assessment of cell type annotation in single-cell transcriptomics data.Briefings in bioinformatics · Sep 1, 2026
EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan.Cancer letters · Aug 28, 2026
Authors' reply to Detection yield, not positive predictive value, is the relevant metric for screening claims.Heart rhythm · Aug 27, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Tempus
Recent articles published on Tempus's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
Tempus AI Bets Big on Whole-Genome Data as Stock Surges Despite Path to Profitability Remains Unclear
The precision medicine company's ambitious plan to scale from 100,000 to one million genomes by 2027 sent shares soaring 31.9%, even as analysts question whether massive datasets can overcome current $254 million losses.
Drug Discovery & Research · Sep 20, 2026
Federal Agency Bets $62.7 Million on Autonomous AI to Replace Missing Cardiologists
ARPA-H awards contracts to six teams racing to build the first FDA-authorized AI agent that can independently manage heart failure patients around the clock.
Clinical AI · Sep 12, 2026
FDA Greenlights Tempus AI's Heart Disease Detector as Wall Street Wrestles With 72-Point Valuation Gap
New cardiovascular AI clearance arrives amid stark disagreement over whether the healthcare data platform is deeply undervalued or wildly overpriced.
Policy & Regulation · Aug 31, 2026
AI Algorithm Detects Hidden Heart Disease From Routine ECG Readings After FDA Green Light
Tempus AI's newly cleared diagnostic tool identifies pulmonary hypertension in symptomatic patients using standard electrocardiograms, expanding AI-driven cardiovascular screening beyond specialty centers.
Clinical AI · Aug 28, 2026
Tempus AI Stock Surges Nearly 19% on Strategic Companion Diagnostics Partnership
The healthcare AI company's integration with CellCarta's commercialization network aims to bridge the gap between FDA approval and real-world clinical deployment for cancer diagnostics.
Clinical AI · Aug 10, 2026
Blood Test Meets AI Platform: New Partnership Aims to Close Alzheimer's Diagnostic Gap for Millions
Lucent Diagnostics and Tempus AI integrate blood-based biomarker testing into EHR workflows, targeting the vast majority of Alzheimer's patients never evaluated for treatment eligibility.
Clinical AI · Jul 25, 2026
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.